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Cancer cell progression and chemoimmunotherapy-dual effects in the
induction of resistance to therapy
J Hamuro, T Kikuchi, F Takatsuki and M Suzuki
Basic Research Laboratories, Central Research Laboratories, Ajinomoto Co., Kawasaki, 210, Japan.
Summary To determine whether resistance to chemoimmunotherapy is acquired during therapy, we
investigated the effects of chemotherapeutic agents and anti-tumour polysaccharide, lentinan, on the
progression of Rous sarcoma virus-induced S908.D2 fibrosarcomas. The chemoimmunotherapy was effective
against the parental S908.D2-bearing mice. Nearly all the mice that were treated with cyclophosphamide (CY)
and lentinan achieved complete tumour regression. Only a few of the mice that achieved complete regression of
the primary tumours showed a recurrence of the tumour in regional lymph nodes. S908.D2-vp.1 was
established from metastatic tumours that developed in the regional lymph nodes of parental S908.D2-bearing
mice during therapy. S908.D2-vp.2-or vp.3 cells were sequentially derived in a similar way from S908.D2-vp. 1-
or-vp.2-bearing mice respectively, im which complete tumour regression at each primary site was achieved
during therapy. These lines acquired resistance to CY and lentinan and also to 5-fluorouracil (5-FU)/5'-deoxy-
5-fluorouracil and lentanin. No significant difference in either the sensitivity to 5-FU or 4-deoxycyclopho-
sphamide in vitro or in the susceptibility to immune effector cells was observed between the parental and
progressed lines (S908.D2-vp.1- -vp.3). There was an increase in the level of prostaglandin E2 (PGE2) in the
progressed lines during repeated therapy (parental, 1171 pg ml-1; vp.1, 2199 pg ml-'; vp.2, 5500 pg m 1-1;
vp3, 16187 pg ml-'). There was no significant increase in the production of transforming growth factor ,B
(TGF-,B). The amount of interleukin-2 (IL-2) produced by spleen cells isolated from the S908.D2-vp.2-bearing
mice was decreased compared with the amount produced by the parental S908.D2-bearing mice. Furthermore,
combination therapy with lentinan and IL-2 achieved complete tumour regression in all the mice transplanted
with S908.D2 progressed tumour lines, although IL-2 alone did not show any anti-tumour effects in either the
S908.D2 parental or progressed lines. The findings suggest that the reduced production of IL-2 induced an
increase in the production of the PGE2 by progressed tumour lines is involved in the acquisition of resistance.
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The genetic instability and heterogeneity of tumour cells are
among the most serious obstacles in the treatment of
cancer patients. Multiple genomic changes in tumour cells
are not only required for the full development of tumour
phenotyes but also for the progression of tumours,
including the acquisition of metastatic traits and resistance
to therapeutic treatments (Vogelstein et al., 1989; Hunter,
1991; Chang and Loeb, 1993). It has been suggested that
oxygen radicals produced by carcinogenic substances and
radiation are involved in the acquisition of genetic
instability (Zimmarman and Cerutti, 1984; Turver and
Brown, 1987; Ward, 1988). Recent studies have shown
that anti-cancer drugs themselves can induce tumour
progression even as they work to destroy tumour cells
(McMillan and Hart, 1987; Imamura et al., 1990). The
resistance to chemotherapeutic agents caused by genetic
changes in tumour cells is one of the factors involved in
tumour progression (Goldie and Coldman, 1979). Studies to
elucidate the mechanisms underlying the acquisition of
resistance to drugs have revealed that many genes, such as
MDRI and GST-7r, are involved in this process (Kramer et
al., 1988; Bradly et al., 1988; Gottesman 1988. Genetic
changes in tumour cells can also result in the escape of
tumour cells from surveillance by host immune system
(Johnson et al., 1989; Tanaka and Tevethia, 1988; Doherty
et al., 1984). Such genetic changes include the loss of target
proteins (tumour-associated antigens), which are usually
recognised by antibodies or cytotoxic T lymphocytes
(CTLs), from the surface of tumour cells, and a decrease
in the expression of major histocompatibility complex
(MHC) class I antigens on tumour cells (Doherty et al.,
1984; Tanaka and Tevethia, 1988).
Recently, many attempts to improve the therapeutic
efficacy of anti-cancer drugs have combined the use of
chemotherapeutic and immunotherapeutic agents (chemoim-
munotherapy). Synergistic effects resulting from such a
combination of treatments have been demonstrated in
experimental models and in clinics (Paciucci et al., 1989;
Mitchell, 1992). We have also observed synergistic anti-
tumour effects against an established murine fibrosarcoma
after treatments with chemotherapeutic agents and an anti-
tumour polysaccharide, lentinan (Suzuki et al., 1994).
Lentinan is a true biological response modifier in the sense
that it lacks direct cytotoxic effects against tumour cells and
is used in combination with tegafur for the clinical treatment
of gastric cancer patients in Japan (Taguchi et al., 1985). It is
not known whether the acquisition of resistance to therapy
occurs during chemoimmunotherapy, or whether the
mechanisms underlying the acquisition of resistance are
distinct from those induced by chemotherapeutic agents or
immune effector cells alone.
In this paper we demonstrate that the acquisition of
resistance to therapy does occur during chemoimmunother-
apy using cyclophosphamide (CY) and lentinan in a murine
fibrosarcoma system. The possible mechansims that lead to
resistance to chemoimmunotherapy were also investigated.
Materials and methods
Mice
BIO.D2 mice were purchased from Shizuoka Laboratory
Animal Center (Shizuoka, Japan). The mice were maintained
in specific pathogen-free conditions. Normal female mice,
6-10 weeks of age, were used for the experiments.
Tumour and target cellsfor cell-mediated cytotoxicity assay
C57BL/6-derived EL-4 thymoma and A/Sn-derived Moloney
virus-induced Yac-1 lymphoma were maintained by culture in
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vitro in RPMI-1640 medium that was supplemented with 5%
fetal bovine serum (FBS). B1O.D2-derived Rous sarcoma
virus (RSV)-induced S908.D2 sarcoma, which was a kind gift
from Dr S Fujimoto of Kochi Medical College, was
maintained by culture in vitro in RPMI-1640 medium that
was supplemented with 5% FBS. For evaluation of anti-
tumour activity, 2 x 106 S908.D2 cells in 0.1 ml of saline were
inoculated intradermally (i.d.) into syngeneic hosts. The
S908.D2-vp.1 subline was isolated from metastatic tumour
cells obtained from the regional lymph nodes of the parental
S908.D2-bearing mice during combination therapy with CY
and lentinan. S908.D2-vp.2 or -vp.3 were isolated in the same
way from metastatic tumour cells from the regional lymph
nodes of mice that had been transplanted with S908.D2-vp.1
or -vp.2 respectively. The S908.D2-nt.1 subline was isolated
from metastatic tumour cells from the regional lymph nodes
ofmice that had been transplanted with the parental S908.D2
and received saline only. S908.D2-nt.2 or -nt.3 were isolated
in the same way from mice that had been transplanted with
S908.D2-nt.1 or -nt.2 respectively. These S908.D2 sublines
were maintained for at least 6 months in RPMI-1640 medium
that was supplemented with 5% FBS.
Reagents
Cyclophosphamide (CY), 5-fluorouracil (5-FU) and 5'-deoxy-
5-fluorouracil (5'-DFUR) were obtained from Shionogi
Pharmaceutical Co. (Osaka, Japan), Kyowa Hakko,
(Tokyo, Japan) and Nippon Roche (Tokyo, Japan) respec-
tively. 4-Deoxy cyclophosphamide was a kind gift from Dr T
Yoshioka of Shionogi Pharmaceutical Co. Poly-I:C was
obtained from Sigma (St Louis, MO, USA.). Recombinant
murine interferon-y (IFN-y) was obtained from Genzyme
(Cambridge, MA, USA) and its specific activity was 1 x 107
units mg-1. Recombinant human interleukin-2 (IL-2) was
prepared as described elsewhere (Satoh et al., 1987) and its
specific activity was 5 x 107 units mg-'. Lentinan, a fully
purified P-1,3-glucan with ,B-1,6 branches obtained from
Lentinus edodes, was prepared as described elsewhere
(Chihara et al., 1969).
Evaluation ofanti-tumour activity
Approximately 2 x 106 S908.D2 lines were inoculated i.d. into
B10.D2 mice. For chemoimmunotherapy either 100 mg kg-1
CY, 75 mg kg-1 5-FU, 130 mg kg-1 5'DFUR or saline was
administered intraperitoneally (i.p.) into mice 10 days after
tumour inoculation. Seven days after the injection of a
chemotherapeutic agent, 5 mg kg-' lentinan or saline was
administered i.p. daily for five consecutive days. For
combined immunotherapy, 5 mg kg- lentinan or saline
was administered i.p. into mice daily for 4 days starting 10
days after tumour inoculation. After the final day of injection
of lentinan, 0.1 mg kg-' (2 jug per mouse) IL-2 or saline was
administered i.p. twice a day for 4 days. Therapeutic activity
was evaluated by the inhibition of tumour growth and the
prolongation of survival days. The size of each tumour was
represented as the product of the largest tumour diameter
and the shortest diameter (mm2).
In vitro susceptibility of S908.D2 lines against
chemotherapeutic agents
Approximately 2 x 104 cells per well of each S908.D2 line
were cultured in 96-well flat-bottom culture plates with
various concentrations of 5-FU or 4-deoxycyclophosphamide.
After 48 h culture, cell growth was examined by an MTT
assay as described elsewhere (Mosmann, 1983).
Preparation of cytotoxic T lymphocytes (CTLs) against
S908.D2
B1O.D2 mice were immunised i.p. twice with 5 x 106 cells
of an 88 Gy irradiated S908.D2 parental line at an
interval of 2 weeks. One week after the final immunisation,
spleen cells were prepared from the immunised mice and
cultured for 5 days with an 88 Gy irradiated S908.D2
parental line (responder/stimulator (R/S) ratio=300). The
cytotoxic activity against each S908.D2 line was assayed in
a 51Cr-release assay (effector/target (E/T)= 100). The
percentage of specific lysis was calculated by the standard
formula: % specific lysis=(experimental release/sponta-
neous release) (maximum release/spontaneous release)-'
x 100.
Preparation of activated natural killer (NK) and
lymphokine-activated killer (LAK) cells
Approximately 5 x 106 cells ml - of spleen cells were cultured
with 100 ig ml-' poly-I:C for 24 h or with 250 units ml-'
rIL-2 for 3 days. The resultant cells were used as NK or
LAK cells respectively. The cytotoxic activity against each
S908.D2 line was assayed in a 51Cr-release assay (E/T = 100)
as described above.
Preparation of activated macrophages
Approximately 1 x 105 cells per well of peritoneal cells were
cultured in 96-well flat-bottom culture plates with 100 units
ml-' murine IFN-y for 24 h and the resultant cells were used
as activated macrophages. The activated macrophages and
each S908.D2 subline were mixed (E/T= 12.5) and cultured
for 24 h. Cytostatic activity was examined by incorporation
of tritiated thymidine ([3H] TdR) during the last 4 h of the
culture. The percentage of specific inhibition was calculated
by the standard formula:% specific inhibition= (incorpora-
tion of [3H]TdR by tumour cells cultured with macrophages)
(incorporation of [3H] TdR of tumour cells cultured without
macrophages)-' x 100.
Flow cytometric analysis
Each S908.D2 subline was stained with H-2Kd-specific
antiserum (Meiji Nyugyo, Tokyo) or H-2Dd-specific antiser-
um (Meiji Nyugyo) and FITC-conjugated mouse Ig-specific
antiserum (Cedarlane, Ontario, Canada). The fluorescence
intensity was measured by FACScan (Becton Dickinson,
Mountain View, CA, USA).
Assayfor prostaglandin E2 (PGE2)
Approximately 1 x 104 cells ml-' of each S908.D2 line were
cultured for 96 h in RPMI-1640 medium that was
supplemented with 10% FBS. The cells were removed and
the medium was harvested and stored at -110°C until
needed for the PGE2 assay. The amount of PGE2 was
measured using a commercially available enzyme immunoas-
say kit (Amersham, Buckinghamshire, UK) according to the
manufacturer's protocol.
Assayfor transforming growth factor # (TGF-,B)
Approximately 1 x 104 cells ml-' of each S908.D2 line were
cultured in RPMI-1640 medium that was supplemented with
10% FBS. After 96 h the culture medium was replaced with
fresh RPMI-1640. After 24 h of culture, the cells were
removed and the conditioned medium was harvested and
heat-treated at 85°C for 10 min to convert latent forms of
TGF-f into active ones. The resultant samples were stored at
-110°C until needed for the TGF-,B assay. MvlLu cells for
the TGF-,B assay were a kind gift from Dr H Fujiwara of
Osaka University. The growth inhibition assay for TGF-,B
was performed according to the method described elsewhere
(Cheifetz et al., 1987). Briefly, MvlLu cells (1 x 104) )were
cultured for 24 h in 96-well flat-bottom plates with diluted
samples or with control recombinant TGF-,B (King Syuzo
Co., Hyogo, Japan) in RPMI-1640 medium that was
supplemented with 5% FBS. Proliferation was assessed by
determining the uptake of [3H]TdR during a 6 h pulse with
37 kBq of [3H]TdR per well.Cancer progression and chemoimmunotherapy
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Production of IL-2 and assayfor IL:-2 activity
Spleen cells (3 x 106 ml-') from either the S908.D2 parental- or
vp.2-bearing B10.D2 mice were cultured with irradiated
S908.D2 parental or vp.2 cells (1 x 104 ml-') in RPMI-1640
medium that was supplemented with 10% FBS. After
incubation for 2 days, culture supernatants were harvested
and stored at -20°C until use. Supernatants were assayed for
IL-2 activity using an IL-2-dependent T cell line, CTLL-2.
CTLL-2 (4 x 103 per well) were cultured with the supernatants
for 24 h. Proliferation was assessed by determining the uptake
of[3H]TdR during a 4 h pulse with 18.5 kBq [3H]TdR per well.
Results
Acquisition ofresistance to chemoimmunotherapy in progressed
lines
To evaluate the effect of chemoimmunotherapy on tumour
progression, a B1O.D2-derived RSV-induced fibrosarcoma,
S908.D2, was used. S908.D2 was chosen because it exhibits a
slow rate of growth in syngeneic hosts and a resistance to
chemotherapeutic agents. Table I shows the results of the
anti-tumour effects of chemoimmunotherapy against
S908.D2. The B10.D2 mice were inoculated i.d. with 2 x 106
viable S908.D2 tumour cells. CY (100 mg kg-'), 5-FU (75
mg kg-') or 5'-DFUR (130 mg kg-') was administered i.p.
10 days after tumour inoculation. One week after the
chemotherapy, 5 mg kg-' lentinan was administered i.p. for
5 consecutive days. CY, 5-FU or 5'-DFUR alone exerted
only a marginal effect on the inhibition of the growth of the
tumour. Only 3 of 20 mice treated with lentinan alone
showed complete regression (experiments 1-3). Although
higher doses of CY (200 mg kg-') or 5-FU (150 mg kg-')
alone augmented extent of the growth inhibition of the
tumour, no mice that received the therapy entered into
complete remission (data not shown). Treatment with higher
doses of lentinan (15 mg kg-') alone could not augment the
anti-tumour effects. The combination of lentinan and a
chemotherapeutic agent (CY, 5-FU or 5'-DFUR) exerted
synergistic anti-tumour effects and resulted in a complete
regression of the tumour in all mice. Almost all of the mice
treated with lentinan and CY appeared to be completely
cured (>250 days survival), and only a few showed tumour
Table I Anti-tumour effects of chemotherapeutic drugs and/or
lentinan against S908.D2 fibrosarcoma in B1O.D2 mice
Treatments Tumour sizea Complete regressionb
Experiment 1
Control 186.4±31.7 0/7
CY 101.7+ 18.1 0/6
LNT 167.1±17.3 0/7
CY/LNT 4.1+10.2 6/6
Experiment 2
Control 124.8 + 16.8 0/7
5-FU 118.6±27.8 0/7
LNT 109.4±34.4 1/7
5-FU/LNT 48.7 ±28.0 7/7
Experiment 3
Control 164.6+21.8 0/6
5'-DFUR 126.5+30.1 0/6
LNT 78.9+ 64.7 2/6
5'-DFUR/LNT 0.0+0.0 7/7
Approximately 2 x 106 cells from the S908.D2 tumour were
inoculated i.d. on day 0. The mice were treated with saline,
cyclophosphamide (CY) (100 mg kg-'), 5-FU (75 mg kg-'), or 5'-
DFUR (130 mg kg-', i.p.! on day 10 and treated with saline or
lentinan (LNT) (5 mg kg , i.p.) on days 17-21. aTumour size was
represented as the product of the largest tumour diameter and the
shortest tumour diameter(mm2) and evaluated on day 28 (experiment
1), day 35 (experiment 2) or day 32 (experiment 3). bComplete
regression at original site was defined when tumour had not regrown
for more than 60 days.
recurrence in regional lymph nodes (around 10% of the
mice). The metastatic tumours were excised and cultured in
vitro. The established subline was designated S908.D2-vp.1.
S908.D2-vp.2 or -vp.3 sublines were sequentially derived in a
similar way from S908.D2-vp.l- or -vp.2-bearing mice
respectively, in which complete tumour regression at each
primary site was observed during therapy. The S908.D2-nt.1
subline was established from metastatic tumours from the
regional lymph nodes of parental S908.D2-bearing mice
treated with saline only. S908.D2-nt.2 or -nt.3 were
sequentially derived in the same way from mice that had
been transplanted with S908.D2-nt.1 or -nt.2. The therapeutic
efficacy of chemoimmunotherapy against these S908.D2
sublines was examined. Only 60%, 28.5%, or 14.2% of
mice inoculated with S908.D2-vp.1 or -vp.2 or -vp.3
respectively, entered into complete remission after treatment
with lentinan and CY (Table II). In contrast, the
chemoimmunotherapy resulted in a complete regression of
the tumour in all mice inoculated with S908.D2-nt.1 or -nt.2
or -nt.3 (Table II), indicating that these sublines did not
acquire resistance to the chemoimmunotherapy. Hereafter,
the S908.D2-vp.1, -vp.2, -vp.3 cell lines are referred to as
progressed lines.
Characterisation ofthe progressed lines in comparison with the
parental line
The growth rates in vitro and in vivo of the progressed lines
were compared with the growth rates of the parental line. No
increase in the in vivo growth rate was observed in the
progressed lines (data not shown). The rate of growth in vivo
of the progressed lines was slightly less than that of the
parental line (data not shown).
We investigated whether the acquired resistance of the
progressed lines to the combination therapy of lentinan and
CY was due to a decreased sensitivity to CY. S908.D2-vp.3
also acquired resistance to the combination of 5-FU/lentinan
and 5'-DFUR/lentinan (data not shown and Table III).
There was no difference between the parental line and
progressed lines in their sensitivity in vitro to 5-FU or 4-
deoxy-cyclophosphamide, which is the active form of CY
(Figure 1). Furthermore, lentinan did not affect the in vitro
growth of either the parental or progressed lines (data not
shown).
To determine whether the acquired resistance of the
progressed lines to chemoimmunotherapy was due to a
decrease in the susceptibility of tumour cells to immune
effector cells, the susceptibility of S908.D2 lines to CTLs, NK
cells, LAK cells or activated macrophages was examined. As
shown in Table IV, CTLs raised against an S908.D2 parental
line were equally cytotoxic against S908.D2 parental and
progressed lines. NK cells and LAK cells were induced from
B10.D2 spleen cells by culture with 100 Mg ml-' poly I:C or
with 250 u ml-' human rIL-2 respectively. S908.D2 parental
Table II Decreased therapeutic effects ofcombination therapy with
CY and lentinan
S908.D2 lines Tumour sizea Complete regressionb
Parental 0.0±0.0 (day 40) 5/5
vp.1 84.3 + 143.0 (day 42) 3/5
vp.2 86.5 ± 88.5 (day 38) 2/7
vp.3 288.9±147.0 (day 41) 1/7
nt.1 3.7±11.5 (day 42) 10/10
nt.2 0.0± 0.0 (day 38) 9/9
nt.3 0.0±0.0 (day 40) 9/9
aTumour size was represented as the product ofthe largest tumour
diameter and the shortest tumour diameter (mm2) and evaluated
around day40. b Complete regression at original site wasdefinedwhen
tumour had not regrown for more than 80 days. Approximately
2 x 106 cells from the S908.D2 sublines were inoculated i.d. on day 0.
The mice were treated with CY (100 mg kg-', i.p.) on day 10 and
lentinan on days 17-21 (5 mgkg-, i.p.).Cancer progression and chemoimmunotherapy $0 J Hamuro et al
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Table III Anti-tumour effects of 5'-DFUR and lentinan against the
progressed line, S908.D2-vp.3, in BIO.D2 mice
Treatment Tumour sizea Complete regressionb
Control 159.8 +40.0 0/7
5'-DFUR 162.1 +48.5 0/9
5'-DFUR/LNT 129.2+ 38.3 0/9
aTumour size was represented as the product ofthe largest tumour
diameter and the shortest tumour diameter (mm2) and evaluated on
day27. b Complete regression atoriginal sitewasdefinedwhen tumour
had not regrown for more than 60 days. Approximately 2 x 106 cells
from the S908.D2-vp.3 tumourwereinoculated i.d. on day0. Themice
were treated with saline or 5'-DFUR (130 mg kg-l, i.p.) onday 10 and
saline or lentinan (5 mgkg ', i.p.) on days 17-21.
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and progressed lines were both relatively resistant to poly
I:C-activated NK cells and no significant differences in
susceptibility were observed between parental and progressed
lines (Table IV). In contrast, both lines were highly sensitive
to LAK cells. Again, no significant differences in suscept-
ibility to LAK cells were observed (Table IV). Activated
macrophages were induced from BlO.D2 peritoneal cells by
culture with 100 u ml-' murine IFN-y. No significant
differences in susceptibility of these lines to activated
macrophages were observed (Table IV).
The parental lines also expressed relatively high levels of
class I H-2 antigens (H-2Kd and H-2 Dd), and no reduction in
the expression of H-2 antigens was observed in progressed
lines (data not shown).
PGE2 and TGF-f production in S908.D2 parental and the
progressed lines
The results shown in Table IV indicate that both S908.D2
parental and progressed lines were antigenic in immunocom-
petent syngeneic hosts. Since immunosuppression caused by
immunosuppressive factor(s) produced by tumour cells has
been commonly observed in experimental models or in clinics
(Tada et al., 1991; Balch et al., 1984), we determined whether
the acquired resistance was due to an increase in the
Table IV Target susceptibility of S908.D2 parental and the
progressed lines to immune effector cells
Effectors
Activated
Targets NKa LAKb CTLsc macrophagesd
S908.D2 parental 22.7+ 3.5 51.5+0.2 35.0+3.8 93.4+6.5
S908.D2 vp.l 9.3+5.2 53.1+5.6 37.1+0.8 82.1+6.3
S908.D2 vp.2 21.8+6.3 71.4+2.1 40.0+ 3.4 85.2+4.5
S908.D2 vpS3 23.4+ 10.5 56.5+ 6.7 37.7 ± 11.3 91.2±1.5
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Figure 1 In vitro susceptibility to chemotherapeutic drugs of
S908.D2 parental and progressed lines. Approximately 2 x 104
cells per well of each S908.D2 line were cultured in 96-well flat-
bottom culture plates with various concentrations of 5-FU (a) or
4-deoxycyclophosphamide (4-HCY) (b). After 48 h culture cell
growth was examined by MTT assay. One hundred per cent cell
growth indicated the average of each cell growth cultured with
medium alone. Cell lines: S908.D2 parental (0); vp.1 (-); vp.2
(0); and vp.3 (El).
'Annrnximatelv _5 x 1(6 ml-I rnleen cells were c-iiltiredl with l , Ai,}.lxFFiuAnlaLIFly J~^ IV 1111 OFIV,W11 %,VII WVI. k,UILUlVU WILII
8 10 100 ugml-l poly I:C for 24 h. Killing activity was examined by a
4 h 5'Cr-release assay, E/T= 100. Killing activity of the NK cells
against NK-sensitive RL-male 1 cells was 54.7%. bApproximately
5 x 106 ml'- spleen cells were cultured with 250 u ml' IL-2 for 3 days.
Killing activity was examined by a 4 h 51Cr-release assay, E/T= 100.
Killing activity ofthe LAK cells against LAK-sensitive EL-4 cells was
30.1%. cApproximately 3 x 106 ml-I spleen cells from B1O.D2 mice
immunised with S908.D2parental lines werecultured with 1 x 10 ml-l
I irradiated S908.D2 parental cells as stimulator for 5 days. Killing
I activity was examined by a 4 h 51Cr-release assay, E/T= 100.
I dApproximately 1 x 106 mlI- peritoneal cells were cultured with
100 u ml-' IFN-y for 24 h. Cytostatic activity was examined by
incorporation oftritiated thymidine for 4 h, E/T= 12.5.
Table V TGF-,B and PGE2 production by S908.D2 parental and
progressed lines
Tumour lines TGF-f PGE26
S908.D2 parental 480+ 10c 1171 ±15d
S908.D2-vp.l 170+ 100 2199+ 137
S908.D2-vp.2 130+ 190 5500+750
S908.D2-vp.3 290+40 16187+8812
P-valuee >0.05 < 0.05
aApproximately 1 X 104 cellsml-1 each S908.D2 line were cultured
with RPMI-1640 supplemented with 10% FBS for 96 h. The medium
was removed and cells were further cultured in serum-free RPMI for
24 h. The cell-free conditioned medium was harvested for the TGF-,B
assay. The medium for TGF-,B assays was heat-treated at 85°C for
10 min. bApproximately 1 x 104 cells ml-' each S908.D2 line were
cultured with RPMI-1640 supplemented with 10% FBS for 96 h and
the medium was harvested forthePGE2 assay. 'The amount ofTGF-,B
(pg ml-l) in the medium was measured by a bioassay using MvlLu.
The amount of PGE2 (pg ml-') in the medium was measured by an
enzymeimmunoassay kit. 'The statistical significance ofthedifferences
of TGF-,B and PGE2 production between cell lines was evaluated by
the Kruskal-Wallis test.
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production of immunosuppressive factor(s). The production
of TGF-,B and PGE2, the immunosuppressive factors known
to be produced by tumour cells (Ceuppens and Goodwin,
1981; Kehrl et al., 1986), was examined in S908.D2 parental
and progressed lines. No significant increase in the
production of TGF-,B was observed among these lines
(Table V). In contrast, the levels of PGE2 in progressed
lines increased relative to levels in the parental line during
repeated chemoimmunotherapy (P<0.05 by the Kruskal-
Wallis test). The parental line produced relatively low levels
of PGE2 (Table V). Elevated levels of PGE2 were not
observed in S908.D2-nt.1 (1500 pg ml-'), -nt.2 (300 pg ml-')
or -nt.3 (1500 pg ml-').
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Effects ofcombination therapy with lentinan and IL-2 on
progressed lines
Defects in IL-2/IL-2 receptor systems are considered one of
the mechanisms of immunosuppression caused by PGE2
(Krause and Deutsch, 1991; Rappaport and Dodge, 1982;
Parhar and Lala, 1987). To determine whether an increase in
the production ofPGE2 in the progressed lines could result in
defects in IL-2/IL-2 receptor systems, the amount of IL-2
present in culture supernatants after mixed lymphocyte
tumour cultures (MLTCs) was determined using spleen cells
from S908.D2 parental- or S908.D2-vp.2-bearing mice. The
amount of IL-2 in supernatants from MLTCs using spleen
b
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Figure 2 Anti-tumour effects of lentinan and IL-2 against the tumour cell line S908.D2-vp.2 in BIO.D2 mice. Approximately
2 x 106 cells from the S908.D2-vp.2 tumour were inoculated i.d. on day 0. The growth curves of each tumour in mice treated with
saline (i.p.) on days 10-13 and days 14-17 (a), mice treated with lentinan (5 mg kg-l, i.p.) on days 10-13 (b), IL-2 (0.1 mg kg-l
twice per day, i.p.) on days 14-17 (c), and mice treated with both lentinan and IL-2 (d). Tumour size was taken to be the product
of the largest tumour diameter and the shortest tumour diameter (mm2). Each line represents the relative tumour size in the
individual mice.
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cells from S908.D2-vp.2-bearing mice was significantly less
compared with that from S908.D2 parental-bearing mice
(parental; 29.8 u ml-' vs vp.2; 6.3 u ml-'). To compensate
for the decrease in IL-2 levels caused by the overproduction
of PGE2, the parental and progressed lines were treated with
lentinan and IL-2. The results shown in Figure 2 demonstrate
that this combination is fully effective for the S908.D2
parental line (data not shown) as well as the S908.D2-vp.2
line, resulting in a complete cure. IL-2 alone did not produce
any significant anti-tumour effects in either S908.D2-vp.2
(Figure 2) or S908.D2 parental lines (data not shown). These
results suggest that the augmented production of PGE2 in
progressed lines results in the acquisition of resistance to
chemoimmunotherapy that consists of CY/5-FU/5'-DFUR
and lentinan.
Disussion
Many studies have speculated on the mechanisms involved in
the acquisition of resistance to chemotherapeutic agents by
tumour cells (Schimke, 1984; Bradly et al., 1988; Gottesman,
1988; Kramer et al., 1988). These studies reveal at least two
types of drug resistance; one is quite specific for a selected
agent, such as an increase in the amount of dihydrofolate
reductase in methotrexate-selected cells, and the other is less
specific to selecting agents, such as an increase in the level of
P-glycoprotein (Schimke, 1984; Gottesman, 1988). The
resistance observed in our system is distinct from the
inherent resistance against selected chemotherapeutic agents
because the progressed lines were developed during therapy
with CY and lentinan and subsequently acquired resistance to
therapy with 5-FU/5'-DFUR and lentinan (Table III and
data not shown). Furthermore, the resistance is believed to be
distinct from multidrug resistance, such as the increase in the
level of P-glycoprotein, because sensitivity in vitro of the
S908.D2 parental and S908.D2 vp. 1-3 progressed lines to
both 5-FU and 4-deoxycyclophosphamide did not change
(Figure 1).
Several studies have shown that the loss of tumour-
associated antigens and a decrease in the expression of MHC
class I antigens on tumour cells results in the escape of
tumour cells from surveillance by host immune cells (Doherty
et al., 1984; Tanaka and Tevethia, 1988). In the present
study, both susceptibility to CTLs, NK cells, LAK cells or
activated macrophages and expression of MHC class I
antigens between parental and progressed lines did not vary
(Table IV and data not shown). These results indicate that
the acquired resistance of the progressed lines to chemoim-
munotherapy was not due to decreased susceptibility to
immune effector cells.
Many studies have also shown that tumour cell- or host-
derived typical immunosuppressive factors participate in the
depression of host immunity against tumours and in the
subsequent enhancement of tumour growth and metastases
(Ceuppens and Goodwin, 1981; Kehrl et al., 1986). TGF-#
and PGE2 are the immunosuppressive factor(s) indicated so
far (Ceuppens and Goodwin, 1981; Kehrl et al., 1986; Li et
al., 1993). In the present study using an S908.D2 murine
fibrosarcoma, TGF-# does not appear to be involved in the
acquired resistance of the mice to therapeutic drugs (Table
V). We do demonstrate, however, that PGE2 production in
the tumour cells increases gradually during repeated therapy
(Table V). It is well known that PGE2 inhibits both IL-2
production and IL-2 receptor expression on T cells (Krause
and Deutsch, 1991; Rappaport and Dodge, 1982; Parhar and
Lala, 1987). Furthermore, recent studies revealed that PGE2
favours a Th2-type of immune response by inhibiting the
production of IFN-y by Thl T cells (Phipps et al., 1991).
These findings suggest that the defect in the IL-2/IL-2
receptor system is a possible mechanism for the acquired
resistance of progressed lines to chemoimmunotherapy. The
production of IL-2 by spleen cells from S908.D2-vp.2-bearing
mice was markedly decreased compared with that from the
parental S908.D2-bearing mice. Previous studies from our
laboratories have shown that lentinan is able to augment the
responsiveness of immune effector cells to IL-2 but that
lentinan did not augment the production of IL-2 (Hamuro
and Chihara, 1985). Therefore, it may be possible to restore
the depressed responsiveness to IL-2 by the application of
lentinan in vivo and to compensate for the reduced
production of IL-2 by the exogenous infusion of IL-2. The
combination therapy of lentinan and IL-2 was completely
effective against S908.D2-vp.2 (Figure 2). These data suggest
that the increased production of PGE2 and the resulting
reduced production of IL-2 may be involved in the
acquisition of resistance to chemoimmunotherapy in the
progressed S908.D2 lines, although we cannot exclude the
participation of TGF-1 or other soluble factors in different
model systems.
Several mechanisms may be responsible for the augmented
production of PGE2 from progressed lines. Tumour cells that
produce high amounts ofPGE2 have been reported to have an
increase in metastatic properties relative to tumour cells that
produce less PGE2 (Mahan et al., 1985). Since S908.D2-vp.1 to
vp.3 (progressed tumour lines) were established from
metastatic cells in the lymph node, clones producing increased
levels of PGE2 might have been selected for. This possibility
may be excluded, however, because metastatic lines (S908.D2-
nt.1, -nt.2 or -nt.3) from the lymph nodes ofmice that did not
received therapy did not acquire resistance to the same
chemoimmunotherapy and did not show enhanced PGE2
production. Another possibility is that chemoimmunotherapy
itself increases the production of PGE2 in tumour cells. Since
the anti-tumour effects ofchemoimmunotherapy with CY and
lentinan are T cell dependent (M Suzuki et al., unpublished
results), host inflammatory cells may be involved in the
tumour disruption process. Recent reports demonstrated that
oxygen radicals produced by host inflammatory cells induced
the augmentation of PGE2 production by tumour cells and
that the enhanced production of PGE2 from tumour cells is
closely related to the phenotype changes of tumour cells from
benign to malignant (Okada et al., 1990, 1992, 1994). The
elucidation of exact mechanisms for the increased production
of PGE2 during therapy requires further detailed studies. In
summary, the results presented here highlight the importance
ofelucidating the biochemical pathways leading to augmented
PGE2 production during chemoimmunotherapy in order to
understand the mechanisms of tumour progression.
The findings described in this paper demonstrate that
tumour cell progression is also induced in chemoimmu-
notherapy, as it is in chemotherapy. The elucidation of the
regulatory mechanisms of tumour cell progression in vivo
during chemoimmunotherapy may result in new methods for
the treatment of cancer patients, such as combination therapy
with lentinan and IL-2.
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